Novatio Ventures
Novatio Ventures Inc is a venture capital firm established in 2015 and headquartered in Toronto, Canada, with additional offices in Boston, Massachusetts, and Hong Kong. The firm specializes in seed and early-stage investments, primarily focusing on high-impact life sciences technologies, including therapeutics, diagnostics, devices, and drug delivery systems. Novatio Ventures aims to accelerate the commercialization of innovations in these sectors, targeting firms that are transitioning from preclinical proof-of-concept to validation. The firm actively collaborates with inventors, entrepreneurs, and institutions to develop and implement effective commercialization strategies, assemble management teams, and secure further capital. With an emphasis on markets in Canada, the United States, China, and South Korea, Novatio Ventures leverages its extensive industry network and collective experience to seek early exits that deliver attractive, risk-mitigated financial returns.
WinterLight Labs
Seed Round in 2017
WinterLight Labs Inc. is a Toronto-based company that specializes in developing a speech-based platform for detecting cognitive and mental diseases, including dementia and Alzheimer’s disease. Founded in 2015, the company utilizes artificial intelligence to analyze and quantify speech and language patterns, allowing for the accurate identification and monitoring of cognitive impairments. The platform can assess a person's cognitive, acoustic, and linguistic state from a brief one-minute speech sample, evaluating aspects such as lexical diversity, syntactic complexity, semantic content, and articulation. WinterLight Labs' technology has significant applications in clinical trials, long-term and primary care, and speech-language pathology, enabling healthcare professionals to track the progression of cognitive conditions effectively.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.